The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents.

La‐Beck, Ninh M.; Wu, Huali; Infante, Jeffrey R.; Jones, Suzanne F.; Burris, Howard A.; Keedy, Vicki L.; Kodaira, Hiroshi; Ikeda, Satoshi; Ramanathan, R. K.; Zamboni, W.

doi:10.1200/jco.2010.28.15_suppl.e13003

Cited by 10 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, the age‐related effects may be altered in certain patient populations. Also, in both male and female patients, age did not appear to affect the CL of IHL‐305 52 …”

Section: Agementioning

confidence: 87%

“…This age cutoff was based on previous studies of PEGylated liposomal anticancer agents using these categories 51 . Age and gender influences have also been evaluated retrospectively in PK studies of Doxil ( n = 70), PEGylated liposomal irinotecan (IHL‐305) ( n = 39), and S‐CKD602 ( n = 45) in patients with solid tumors and Kaposi's sarcoma 52 . Male patients <60 years of age had a 2.2‐fold higher CL of Doxil and a 2.1‐fold higher CL of S‐CKD602 as compared with male patients ≥60 years of age 52 .…”

Section: Agementioning

confidence: 99%

“…Gender was also found to be one of the many factors contributing the PK and PD variability of CMAs. The effect of gender on CL of Doxil ( n = 70), IHL‐305 ( n = 39), and S‐CKD602 ( n = 45), with and without stratification by age, was evaluated in PK studies conducted as part of phase I and phase II studies 52 . Female patients had a 2.4‐fold lower overall CL of Doxil ( P < 0.001), a 1.4‐fold lower overall CL of IHL‐305 ( P = 0.068), and a 1.3‐fold lower overall CL of S‐CKD602 ( P = 0.67) as compared with male patients 52 .…”

Section: Gendermentioning

confidence: 99%

See 2 more Smart Citations

Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier-Mediated Anticancer Agents

Caron

Song

Kumar

et al. 2012

Clin Pharmacol Ther

View full text Add to dashboard Cite

Major advances in the field of carrier-mediated agents (CMAs) have revolutionized drug delivery capabilities over the past decade. While providing numerous advantages over their small-molecule counterparts (solubility,duration of exposure, and delivery to the site of action are higher), these agents display substantial variability in systemic clearance (CL) and distribution, tumor delivery, and pharmacologic effects. This review provides an overview of factors that affect the pharmacokinetics (PK) and pharmacodynamics (PD) of CMAs in preclinical models and patients.

show abstract

“…Consequently, the age‐related effects may be altered in certain patient populations. Also, in both male and female patients, age did not appear to affect the CL of IHL‐305 52 …”

Section: Agementioning

confidence: 87%

Section: Agementioning

confidence: 99%

Section: Gendermentioning

confidence: 99%

See 1 more Smart Citation

Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier-Mediated Anticancer Agents

Caron

Song

Kumar

et al. 2012

Clin Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In terms of efficacy, an increase in age was found to be inversely proportional with progression-free survival; however, no correlation between age and overall survival was found [47]. Alterations in the PK and PD of CMA may involve age-related decline in immune system functioning, specifically the association of aging to the function of monocytes [48]. In theory, there is a loss of MPS activity or function in elderly patients which decreases the clearance of CMA by MPS and leads to increased drug exposures and toxicity in elderly patients.…”

Section: Agementioning

confidence: 99%

The Effects of Nanoparticle Drug Loading on the Pharmacokinetics of Anticancer Agents

Petschauer

Madden

Kirschbrown

et al. 2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Major advances in carrier-mediated agents, which include nanoparticles, nanosomes and conjugates, have revolutionized drug delivery capabilities over the past decade. While providing numerous advantages, such as greater solubility, duration of exposure and delivery to the site of action over their small-molecule counterparts, there is substantial variability in systemic clearance and distribution, tumor delivery and pharmacologic effects (efficacy and toxicity) of these agents. This review provides an overview of factors that affect the pharmacokinetics and pharmacodynamics of carrier-mediated agents in preclinical models and patients.

show abstract

“…There has been a recent increase in attention towards sex-specific medicine 17 . Foci include the study of 45 female-specific administration routes, such as vaginal delivery [18][19][20] , and evaluation of sex differences in pharmacokinetic parameters of clinically-approved nanomedicines 21 . PEGylated liposomal doxorubicin 47 has a slower overall clearance rate in females than in males 21 .…”

Section: Introductionmentioning

confidence: 99%

Chemotherapeutic Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Fertility and Anticancer Activity

Poley

Shammai

Kaduri

et al. 2020

Preprint

View full text Add to dashboard Cite

Throughout the female menstrual cycle, physiological changes occur that affect the biodistribution of nanoparticles within the reproductive system. This can have positive or negative effects. We demonstrate a 2-fold increase in nanoparticle accumulation in the ovaries during female mouse ovulation compared to the non-ovulatory stage following intravenous administration. Accumulation in the reproductive system is favored by nanoparticles smaller than 100 nm. Chemotherapeutic nanoparticles administered during ovulation increased ovarian toxicity and decreased short-term and long-term fertility when compared to the free drug. Breast cancer treated with nanomedicines during ovulation results in higher drug accumulation in the reproductive system rather than at the site of the tumor, reducing treatment efficacy. Conversely, ovarian cancer treatment was improved by enhanced nanoparticle accumulation in the ovaries during ovulation. Our findings suggest that the menstrual cycle should be considered when designing and implementing nanotherapeutics for females.

show abstract

The evaluation of gender on the pharmacokinetics (PK) of pegylated liposomal anticancer agents.

Cited by 10 publications

References 0 publications

Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier-Mediated Anticancer Agents

Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier-Mediated Anticancer Agents

The Effects of Nanoparticle Drug Loading on the Pharmacokinetics of Anticancer Agents

Chemotherapeutic Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Fertility and Anticancer Activity

Contact Info

Product

Resources

About